AnHorn Medicines, a Taiwan-based biotech company, on Wednesday reported positive results from its US Phase I clinical trial of AH-001, an AI-generated topical protein degrader developed for the treatment of androgenetic alopecia (male pattern hair loss).

AH-001 is a novel, AI-designed small molecule that works through a targeted protein degradation mechanism to selectively eliminate the androgen receptor, a key driver in hormone-related hair loss.

The trial confirmed that the product was safe and well-tolerated across all dose levels, with no drug-related adverse events. According to AnHorn, this represents the first successful completion of a US human clinical trial for an AI-designed new drug originating from Taiwan, underscoring the clinical viability and precision design capability of the company's proprietary AI platform.

AH-001 is designed to be applied topically, directly addressing the root cause of androgenetic alopecia while avoiding the systemic side effects commonly associated with oral hormonal inhibitors such as finasteride.

Preclinical and Phase I data demonstrated a strong safety profile and excellent local tolerability, setting the stage for dose optimisation and efficacy trials in Phase II.

AH-001 is being advanced as a topical, next-generation therapy for adults aged 20 to 50.